Literature DB >> 18551100

Asymmetric dimethylarginine (ADMA) has a role in regulating systemic vascular tone in young healthy subjects: the cardiovascular risk in young Finns study.

Hannu Päivä1, Mika Kähönen, Terho Lehtimäki, Olli T Raitakari, Antti Jula, Jorma Viikari, Georg Alfthan, Markus Juonala, Reijo Laaksonen, Nina Hutri-Kähönen.   

Abstract

BACKGROUND: This study was designed to evaluate whether plasma asymmetric dimethylarginine (ADMA) has any role in predicting hemodynamic responses in clinically healthy young subjects. ADMA, as an endogenous nitric oxide (NO) synthase inhibitor, has been demonstrated to associate with hypertension and vascular reactivity in experimental but not undoubtedly in physiological settings.
METHODS: A total of 199 subjects aged 31.4 years (range 24-39 years) were studied. Plasma ADMA and symmetric dimethylarginine (SDMA) were assessed by isocratic high-pressure liquid chromatography using precolumn derivatization with o-phtaldialdehyde at baseline. Blood pressure (BP) was measured by casual measurements in the beginning of the study and after a follow-up period of 2.45 +/- 0.42 years (range, 1.86-3.19 years). Hemodynamic regulation was assessed by noninvasive methods after a follow-up.
RESULTS: Plasma ADMA had a negative association with resting systemic vascular resistance index (SVRI) (r = -0.23, P < 0.01) and pulse wave velocity (PWV) (r = -0.17, P < 0.05) and positive association with cardiac index (CI) (r = 0.21, P < 0.01) after the follow-up. Plasma ADMA had also negative association with responses of SVRI (r = -0.19, P < 0.01) and positive association with CI (r = 0.25, P < 0.001) in a hemodynamic reactivity test. In a multivariate linear model (R2 = 0.20, P < 0.00001), diastolic BP (R = 0.37, P < 0.00001) and ADMA (R = -0.20, P < 0.01) were significant predictors of SVRI.
CONCLUSIONS: These results suggest that plasma ADMA seems to play a role in the regulation of vascular tone in young healthy subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551100     DOI: 10.1038/ajh.2008.215

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

1.  Impact of arterial stiffness on adverse cardiovascular outcomes and mortality in peritoneal dialysis patients.

Authors:  Murat H Sipahioglu; Hamit Kucuk; Aydin Unal; Mehmet G Kaya; Fatih Oguz; Bulent Tokgoz; Oktay Oymak; Cengiz Utas
Journal:  Perit Dial Int       Date:  2011-03-31       Impact factor: 1.756

2.  Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients.

Authors:  Sena Memnune Ulu; Seref Yuksel; Atila Altuntaş; Emre Kacar; Ahmet Ahsen; Abdullah Altug; Sefa Celik; M Tugrul Sezer
Journal:  Int Urol Nephrol       Date:  2014-06-08       Impact factor: 2.370

3.  Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes.

Authors:  Eugenia Gkaliagkousi; Eleni Gavriilaki; Areti Triantafyllou; Barbara Nikolaidou; Panagiota Anyfanti; Nikolaos Koletsos; Anastasios Vamvakis; Konstantina Dipla; Antonios Lazaridis; Stella Douma
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-15       Impact factor: 3.738

4.  The role of increased glucose on neurovascular dysfunction in patients with the metabolic syndrome.

Authors:  Sara Rodrigues; Felipe X Cepeda; Edgar Toschi-Dias; Akothirene C B Dutra-Marques; Jefferson C Carvalho; Valéria Costa-Hong; Maria Janieire N N Alves; Maria Urbana P B Rondon; Luiz A Bortolotto; Ivani C Trombetta
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-04       Impact factor: 3.738

Review 5.  Restoration of asymmetric dimethylarginine-nitric oxide balance to prevent the development of hypertension.

Authors:  You-Lin Tain; Li-Tung Huang
Journal:  Int J Mol Sci       Date:  2014-07-02       Impact factor: 5.923

6.  Asymmetric dimethylarginine is not a marker of arterial damage in children with glomerular kidney diseases.

Authors:  Piotr Skrzypczyk; Joanna Przychodzień; Małgorzata Mizerska-Wasiak; Elżbieta Kuźma-Mroczkowska; Anna Stelmaszczyk-Emmel; Elżbieta GóRSKA; Małgorzata Pańczyk-Tomaszewska
Journal:  Cent Eur J Immunol       Date:  2020-01-20       Impact factor: 2.085

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.